Vanguard Reports 0 Shares of Dyne Therapeutics
Dyne Therapeutics Inc ownership update: The Vanguard Group filed an amended Schedule 13G/A stating it reports no beneficial ownership of Dyne Therapeutics common stock following an internal realignment.
Rhea-AI Filing Summary
Dyne Therapeutics Inc ownership update: The Vanguard Group filed an amended Schedule 13G/A stating it reports no beneficial ownership of Dyne Therapeutics common stock following an internal realignment. The filing lists Amount beneficially owned: 0 and Percent of class: 0%.
The filing cites an internal realignment effective January 12, 2026 and is signed on 03/26/2026.
Positive
- None.
Negative
- None.
Insights
Vanguard disaggregated holdings and reports zero beneficial ownership of Dyne.
The disclosure states The Vanguard Group completed an internal realignment on January 12, 2026 and, in reliance on SEC Release No. 34-39538, now reports holdings of certain subsidiaries separately. The form records 0 shares and 0% ownership.
Cash‑flow treatment and specific subsidiary holdings are not listed in this excerpt; subsequent filings by Vanguard subsidiaries may show where prior holdings are reported.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did The Vanguard Group report for DYN in this amendment?
Why does Vanguard now report zero ownership of Dyne (DYN)?
What date is the signature and who signed the amendment?
AI-generated analysis. How Rhea-AI works. Not financial advice.